National Health (Immunisation Program – Designated Vaccines) Amendment Determination (No. 1) 2020 (Cth)

National Health (Immunisation Program – Designated Vaccines) Amendment Determination (No.1) 2020

I, Hope Peisley, delegate of the Minister for Health, make the following Determination.

Dated   28 April 2020 

Hope Peisley

Assistant Secretary
Office of Health Protection
Chief Medical Officer Group
Department of Health

Contents

1  Name........................................................................................................................................ 2

2  Commencement........................................................................................................................ 2

3  Authority.................................................................................................................................. 2

4  Schedules................................................................................................................................. 2

Schedule 1—Amendments  3

National Health (Immunisation Program – Designated Vaccines) Determination 2014 (No.1)      3

1 Name

This instrument is the National Health (Immunisation Program – Designated Vaccines) Amendment Determination (No. 1) 2020.

2 Commencement

(1)  Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1.  The whole of this instrument.	The day after this instrument is registered.

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under section 9B of the National Health Act 1953.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Immunisation Program – Designated Vaccines) Determination 2014 (No.1)

1. Before subsection 7(1)

Insert:

(1A)     For item 108A of Schedule 1, the following number of doses and booster doses of a designated vaccine mentioned in that item may be provided to a person who has congenital or acquired asplenia (e.g. splenectomy) or hyposplenia; a person who has complement deficiency or a person undergoing eculizumab treatment:

(a)Primary doses according to the following number of doses:

(i)   if aged 6 weeks to 5 months at the start of their vaccine course – 4 doses;

(ii)    if aged 6 to 11 months at the start of their vaccine course – 3 doses; or

(iii)  if aged 12 months or older at the start of their vaccine course – 2 doses;

(b)plus booster doses according to the following number and timing of doses:

(iv)  if they completed their primary schedule at less than or equal to 6 years of age - 1 booster dose 3 years after completing the primary schedule, and then 1 booster dose every 5 years after that; or

(v)    if they completed their primary schedule at 7 years of age or older - 1 booster dose every 5 years after completing the primary schedule.

2    After paragraph 7(1) (a)

Insert:

(b)        a dose of the vaccine may be provided to a person:

(i)        who is about 6 months of age and has one or more of the following medical risk conditions:

(A)      functional or anatomical asplenia including sickle cell disease, other haemoglobinopathies, congenital or acquired asplenia (e.g. splenectomy) or hyposplenia; or

(B)       immunocompromising conditions including congenital or acquired immune deficiency including symptomatic IgG subclass or isolated IgA deficiency, haematological malignancies, solid organ transplant haematopoietic stem cell transplant (HSCT) or HIV infection; or

(C)       chronic respiratory disease including suppurative lung disease, bronchiectasis and cystic fibrosis or chronic lung disease of prematurity; or

(D)       chronic renal disease including: end stage renal disease –  eGFR <15mL/min or relapsing or persistent nephrotic syndrome; or

(E)       proven or presumptive cerebrospinal fluid (CSF) leak; or

(F)        cochlear implants; or

(G)       intracranial shunts; or

(H)       previous episode of invasive pneumococcal disease (IPD); or

(I)        born less than 28 weeks gestation; or

(J)        trisomy 21; or

(K)       chronic heart disease including cyanotic heart disease and heart failure;

(ii)       who is at least 12 months and less than 5 years of age and has been newly diagnosed with one or more of the medical risk conditions contained in subparagraph (b)(i);

(iii)      who is at least 5 years of age and has been newly diagnosed with one or more of the medical risk conditions contained in subparagraphs (b)(i)(A)-(H);

(c)        a dose of the vaccine may be provided to a person:

(i)         who is an Aboriginal and/or Torres Strait Islander; and

(ii)        who is at least 50 years.

(d)        a dose of the vaccine may be provided to a person:

(i)         who is not an Aboriginal and/or Torres Strait Islander; and

(ii)        who is at least 70 years.

3 Subsection 7(2)

Repeal subsection 7(2), substitute:

(2)       For item 112 of Schedule 1, a designated vaccine in that item may be provided in the following circumstances:

(a)        a first dose of the vaccine may be provided to a person:

(i)        who is at least 4 years but less than 6 years and has one or more of the following medical risk conditions:

(A)       functional or anatomical asplenia including sickle cell disease or other haemoglobinopathies, congenital or acquired asplenia (e.g. splenectomy) or hyposplenia; or

(B)       immunocompromising conditions including congenital or acquired immune deficiency including symptomatic IgG subclass or isolated IgA deficiency, haematological malignancies, solid organ transplant haematopoietic stem cell transplant (HSCT) or HIV infection; or

(C)       chronic respiratory disease including suppurative lung disease, bronchiectasis and cystic fibrosis or chronic lung disease of prematurity; or

(D)       chronic renal disease including end stage renal disease –  eGFR <15mL/min, relapsing or persistent nephrotic syndrome; or

(E)        proven or presumptive cerebrospinal fluid (CSF) leak; or

(F)        cochlear implants; or

(G)       intracranial shunts; or

(H)       previous episode of invasive pneumococcal disease (IPD); or

(I)         born less than 28 weeks gestation; or

(J)        trisomy 21; or

(K)      chronic heart disease including cyanotic heart disease and heart failure;

(ii)       who is aged at least 5 years and has been newly diagnosed with one or more of the medical risk conditions contained in subparagraphs (a)(i)(A)-(H);

(iii)      who is an Aboriginal and/or Torres Strait Islander aged at least 4 years but less than 6 years and who lives in Queensland, Western Australia, South Australia or the Northern Territory;

(iv)      who is an Aboriginal and/or Torres Strait Islander aged at least 50 years and who has not received a dose of the vaccine under (ii);

(b)      a second dose of the vaccine may be provided to a person mentioned in paragraph (a) at least 5 years after the first dose was provided to the person under paragraph (a). 

4 Part 1 of Schedule 1 (table item 103, column headed “Vaccine and the circumstances in which vaccine may be provided”)

Repeal the circumstances, substitute:

Circumstances

Vaccine may be provided to:

(a)    a child who is about 18 months old; or

(b)   a person who is at least 5 years old and who has congenital or acquired asplenia (e.g. splenectomy) or hyposplenia and did not receive childhood vaccinations.

5 Part 1 of Schedule 1 (table item 108A, column headed “Vaccine and the circumstances in which vaccine may be provided”)

Repeal the circumstances, substitute:

Circumstances

Vaccine may be provided to:

a)   a child who is 12 months old; or

b)   a person who is at least 14 years old but less than 20 years of age; or

c)   a person who has congenital or acquired asplenia (e.g. splenectomy) or hyposplenia; or

d)   a person who has complement deficiency; or

e)   a person undergoing eculizumab treatment.

6 Part 1 of Schedule 1 (table item 108A, column headed “Number and timing of doses”)

Repeal the doses, substitute:

1 dose

If in circumstances (c), (d) or (e): 2 to 4 doses of a primary course plus booster doses as described in subsection 7(1A)

7 Part 1 of Schedule 1 (table item 110, column headed “Vaccine and the circumstances in which vaccine may be provided”)

Omit “(b) to a child who is about 6 months of age and is a member of a medical risk group”.